NDAINJECTIONINJECTABLE
Approved
Nov 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CITANEST FORTE DENTAL (epinephrine bitartrate; prilocaine hydrochloride) by AstraZeneca is mechanism of action prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 1965.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CITANEST FORTE DENTAL is a local anesthetic combination injectable containing prilocaine hydrochloride and epinephrine bitartrate, approved in 1965 for dental anesthesia. Prilocaine stabilizes neuronal membranes to block pain signal initiation and conduction, while epinephrine provides vasoconstriction to extend duration and reduce systemic absorption. It is indicated for infiltration and nerve block anesthesia in dental procedures.
LOE Approaching
Product lifecycle approaching loss of exclusivity signals consolidation or divestment priorities within AstraZeneca's specialty pharmaceutical portfolio; team staffing likely focused on transition planning rather than growth.
Mechanism of Action
Mechanism of Action Prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings, CITANEST FORTE DENTAL represents a low-opportunity product for career growth within AstraZeneca. Roles available are primarily defensive—focused on protecting market share, ensuring regulatory compliance, and managing the transition to generic competition rather than driving revenue expansion or innovation.
Brand Manager
Worked on CITANEST FORTE DENTAL at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.